The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
To address the challenge of antimicrobial resistance (AMR) it is imperative that the current finite pool of antimicrobial agents is optimised, to maximise therapeutic success, limit the risk of drug toxicity, whilst minimising emergence of resistance. Outside of the critical care setting it is not known how many patients are receiving optimal drug concentrations for the treatment of infection. This study aims to assess whether antimicrobial targets are being achieved in these individuals and explore how clinical co-variates and outcomes may relate to this. Furthermore, it aims to identify priority groups and/or drugs where there are gaps in dose optimisation research and develop hypotheses which can be tested in observational studies. Eligible participants will be enrolled and observed during their management of infection at Imperial College NHS Trust. After providing informed consent their clinical data will be collected from electronic healthcare records and they will provide samples that will undergo drug concentration analysis.
Study Type
OBSERVATIONAL
Enrollment
323
Imperial College Healthcare NHS Trust
London, United Kingdom
RECRUITINGDetermine the number of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
Determine the number of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved
Time frame: 3 years
Find the number of individuals receiving co-administered non-beta-lactam antibiotics in whom drug concentration targets are achieved.
Find the number of individuals receiving co-administered non-beta-lactam antibiotics in whom drug concentration targets are achieved.
Time frame: 3 years
Show how clinical co-variates, co-administered medications and treatment outcomes relate to target attainment, and identify groups of patients in who therapeutic drug monitoring may be beneficial.
Show how clinical co-variates, co-administered medications and treatment outcomes relate to target attainment, and identify groups of patients in who therapeutic drug monitoring may be beneficial.
Time frame: 3 years
Illustrate dynamic patterns of infection-related biomarkers which may indicate the presence/absence of treatment response.
Illustrate dynamic patterns of infection-related biomarkers which may indicate the presence/absence of treatment response.
Time frame: 3 years
Show how drug-levels obtained through minimally invasive sampling and the use of residual specimens relate to blood, and how these could be used to inform individual dose-optimisation.
Show how drug-levels obtained through minimally invasive sampling and the use of residual specimens relate to blood, and how these could be used to inform individual dose-optimisation.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Build a repository of real life PK-PD data which can be used to generate hypotheses and guide the development of interventional dose optimisation studies
Build a repository of real life PK-PD data which can be used to generate hypotheses and guide the development of interventional dose optimisation studies
Time frame: 3 years